Gastrointestinal AE with cagrisema were more than with semagutide or cagrilintide monotherapy, however the SAE and AE leading to medication discontinuation were minimal and similar between the groups [87, 90] A programme of phase 3 clinical trials (REDEFINE) assessing the safety and efficacy of cagrisema in people with obesity (NCT05567796, NCT05394519, NCT05813925) is currently ongoing
Tell your brain youre full, stimulate insulin release when blood sugar rises, slow gastric emptying, suppress glucagon secretion
Genes exhibiting false discovery rate (FDR)-adjusted P 2 were considered significant and subjected to further analysis
VH: Project administration, Writing review & editing
Temporary adjustments in bowel movements, including mild diarrhea, constipation, or transient bloating
Predictors of relapse in alcohol use disorder: identifying individuals most vulnerable to relapse